GB2350565A - Biological wound dressings comprising mitochondria - Google Patents
Biological wound dressings comprising mitochondria Download PDFInfo
- Publication number
- GB2350565A GB2350565A GB9912572A GB9912572A GB2350565A GB 2350565 A GB2350565 A GB 2350565A GB 9912572 A GB9912572 A GB 9912572A GB 9912572 A GB9912572 A GB 9912572A GB 2350565 A GB2350565 A GB 2350565A
- Authority
- GB
- United Kingdom
- Prior art keywords
- mitochondria
- composition
- dispersed
- wound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition for use in the treatment of wounds, wherein the composition comprises dispersed mitochondria. The invention also provides a process to prepare a composition for use in the treatment of wounds, said process comprising the step of isolating mitochondria from the cells of an organism, and dispersing the mitochondria in or on a vehicle for application of the mitochondria to a wound. The composition may comprise an ointment or a solid carrier such as a wound dressing in which the mitochondria are dispersed.
Description
23,50565 BIOLOGICAL WOUND DRESSINGS This invention relates to the use of
mitochondria for treating chronic wounds.
Chronic wounds are wounds that fail to heal spontaneously. They are mostly found in older patients and are associated with, for example, venous insufficiency or diabetes.
They may also arise following prolonged pressure in bedridden or wheelchair bound patients when they are known as decubitus ulcers.
Currently, chronic wounds are treated in a variety of ways depending upon the underlying condition of the patient. Commonly, an attempt is made to correct the underlying problem, for example by providing compression bandaging in the case of venous insufficiency or parenteral insulin in cases of diabetes. The chronic wound is cleaned then dressed with a hydrogel/colloid based material having appropriate gaseous exchange characteristics that maintains a warm and moist wound environment. Antimicrobial agents are also used. Most recently, wound management materials that deliver a growth factor to the wound have been developed, as have materials constructed from living cells. Although increases in the rate of healing do occur, rates of healing of chronic wounds do not yet approach rates observed in normal wounds. 20 It has now been proposed that if a preparation of mitochondria is delivered to the bed of the chronic wound, preferably in such a manner as to implant said mitochondria within the cells of the wound bed, enhanced healing can be achieved.
Accordingly, the present invention provides a composition for use in the treatment of wounds, wherein the composition comprises dispersed mitochondria.
The term "dispersed mitochondria" refers to mitochondria that are substantially intact, but that are no longer retained within the cytoplasm of individual cel - Is. That is to say free mitochondria such as those obtained by isolating mitochondria from cells. Preferably, the compositions according to the present invention are substantially free of intact cells. More preferably, the compositions according to the present invention are substantially free of cellular organelles other than mitochondria.
2 Preferably, the compositions according to the present invention comprise at least I ppm, more preferably at least 10 ppm, and most preferably at least 100 ppm by weight of the said dispersed mitochondria. Preferably, the compositions comprise conventional 5 excipients such as water, gelling agents such as carboxymethy1cellulose or hydroxyethylcellulose, antiseptics, etc. Preferably, the compositions according to the present invention are ointments for application to a wound.
Preferably, the compositions include means to assist penetration of the mitochondria 10 into the cells of the wound bed. For example, the compositions preferably comprise liposomes.
In other preferred embodiments, the composition comprises a solid carrier having the said mitochondria dispersed thereon. Preferably, the solid carrier is a wound dressing 15 film, foam, sponge or fabric.
The composition according to the present invention may be applied under an appropriate secondary dressing, for example an air-permeable membrane.
Alternatively, the mitochondria may be treated in such a way as to preserve them and render them suitable for delivery using a high velocity microparticulate delivery technology. Preferably, the compositions according to this aspect of the present invention comprise mitochondria dispersed on solid particles, such as gold particles, less than I jun in diameter.
Preferably, the mitochondria are derived from cells of animal origin, more preferably from cells that are normally well-endowed with mitochondria, for example cultured hepatocytes.
In other preferred embodiments of the invention, the mitochondria are derived from cells of fungal origin, preferably young cells, more preferably cultured yeast cells.
3 in further preferred embodiments of the invention, the mitochondria are derived from cells of bacterial or algal or protozoal origin, preferably young cells.
The mitochondria useful in this invention may be isolated from living cells by methods well known in the art. They may be stabilised and preserved by methods applied by those skilled in the art of cryopreservation of living cells, using cryopreservation agents, for example trehalose or surfactants sold under the Registered Trade Mark PLURONIC Accordingly, the present invention further provides a process to prepare a composition for use in the treatment of wounds, said process comprising the step of isolating mitochondria from the cells of an organism, and dispersing the mitochondria in or on a vehicle for application of the mitochondria to a wound.
Preferably, the process is adapted for the preparation of a composition according to the present invention.
The present invention further provides the use of mitochondria isolated from the cells of an organism for the preparation of a medicament for the treatment of a wound.
Preferably, the wound is a chronic wound. More preferably, the wound is selected from the group consisting of venous ulcers, decubitis ulcers and diabetic ulcers.
4
Claims (14)
1. A composition for use in the treatment of wounds, wherein the composition comprises dispersed mitochondria.
2. A composition according to claim 1, wherein the composition comprises at least I ppm by weight of the said dispersed mitochondria.
3. A composition according to claim 2, wherein the composition comprises at least 10 10 ppm. by weight of the said dispersed mitochondria.
4. A composition according to claim 3, wherein the composition comprises at least 100 ppm by weight of the said dispersed mitochondria.
5. A composition according to any preceding claim, wherein the composition is an ointment for application to a wound.
6. A composition according to any one of claims I to 5, wherein the composition comprises liposomes.
7. A composition according to any preceding claim, wherein the composition comprises a solid carrier having the said mitochondria dispersed thereon.
8. A composition according to claim 7, wherein the solid carrier comprises solid 25 particles less than I tm in diameter.
9. A composition according to any one of claims I to 8, wherein the dispersed mitochondria are of animal origin.
10. A composition according to any one of claims I to 8, wherein the dispersed mitochondria are of fungal origin.
11. A composition according to any one of claims I to 8, wherein the dispersed mitochondria are of bacterial or algal or protozoal origin.
12. A process to prepare a composition for use in the treatment of wounds, said process comprising the step of isolating mitochondria from the cells of an organism, and dispersing the mitochondria in or on a vehicle for application of the mitochondria to a wound.
13. Use of mitochondria isolated from the cells of an organism for the preparation of a medicament for the treatment of a wound. 10
14. Use according to claim 13, wherein the wound is a chronic wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9912572A GB2350565A (en) | 1999-05-28 | 1999-05-28 | Biological wound dressings comprising mitochondria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9912572A GB2350565A (en) | 1999-05-28 | 1999-05-28 | Biological wound dressings comprising mitochondria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9912572D0 GB9912572D0 (en) | 1999-07-28 |
| GB2350565A true GB2350565A (en) | 2000-12-06 |
Family
ID=10854439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9912572A Withdrawn GB2350565A (en) | 1999-05-28 | 1999-05-28 | Biological wound dressings comprising mitochondria |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2350565A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065334A1 (en) * | 2006-11-30 | 2008-06-05 | Systagenix Wound Management Ip Co. B.V. | Wound dressing compositions containing non-viable cell lysate |
| WO2013171752A1 (en) * | 2012-05-16 | 2013-11-21 | Minovia Therapeutics Ltd. | Compositions and methods for inducing angiogenesis |
| EP3747449A4 (en) * | 2018-02-02 | 2021-10-20 | Paean Biotechnology Inc. | Pharmaceutical composition comprising isolated mitochondria for prevention or treatment of rheumatoid arthritis |
| US20220168215A1 (en) * | 2014-09-30 | 2022-06-02 | Taiwan Mitochondrion Applied Technology Co., Ltd. | Use of composition for reducing or preventing cell aging or repairing cell with damaged mitochondria, method of preparing composition for cell repairing, cell repairing method and method of supplying mitochondria into cell |
| US11944642B2 (en) | 2011-09-11 | 2024-04-02 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| US11951135B2 (en) | 2018-07-22 | 2024-04-09 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of muscle diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB866483A (en) * | 1958-08-13 | 1961-04-26 | Georges Claude Velley | Pharmaceutical compositions containing endocellular particles derived from foetal tissue |
| GB1089039A (en) * | 1964-08-31 | 1967-11-01 | Egema | Therapeutic material consisting of mitochondria and compositions containing them |
| GB1256755A (en) * | 1968-06-05 | 1971-12-15 |
-
1999
- 1999-05-28 GB GB9912572A patent/GB2350565A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB866483A (en) * | 1958-08-13 | 1961-04-26 | Georges Claude Velley | Pharmaceutical compositions containing endocellular particles derived from foetal tissue |
| GB1089039A (en) * | 1964-08-31 | 1967-11-01 | Egema | Therapeutic material consisting of mitochondria and compositions containing them |
| GB1256755A (en) * | 1968-06-05 | 1971-12-15 |
Non-Patent Citations (2)
| Title |
|---|
| JP08208678A & WPI Abstract Acc No 96-421982 & JAPIO abstract * |
| JP63044526A & WPI Abstract Acc No 88-094614 & JAPIO abstract * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065334A1 (en) * | 2006-11-30 | 2008-06-05 | Systagenix Wound Management Ip Co. B.V. | Wound dressing compositions containing non-viable cell lysate |
| US20100209481A1 (en) * | 2006-11-30 | 2010-08-19 | Systagenix Wound Management (Us) Inc. | New wound dressing compositions |
| US8834905B2 (en) * | 2006-11-30 | 2014-09-16 | Systagenix Wound Management (Us), Inc. | Wound dressing compositions |
| US10183093B2 (en) | 2006-11-30 | 2019-01-22 | Kci Usa, Inc. | Wound dressing compositions |
| US11944642B2 (en) | 2011-09-11 | 2024-04-02 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| WO2013171752A1 (en) * | 2012-05-16 | 2013-11-21 | Minovia Therapeutics Ltd. | Compositions and methods for inducing angiogenesis |
| US10702556B2 (en) | 2012-05-16 | 2020-07-07 | Minovia Therpautices Ltd. | Compositions and methods for inducing angiogenesis |
| US20220168215A1 (en) * | 2014-09-30 | 2022-06-02 | Taiwan Mitochondrion Applied Technology Co., Ltd. | Use of composition for reducing or preventing cell aging or repairing cell with damaged mitochondria, method of preparing composition for cell repairing, cell repairing method and method of supplying mitochondria into cell |
| EP3747449A4 (en) * | 2018-02-02 | 2021-10-20 | Paean Biotechnology Inc. | Pharmaceutical composition comprising isolated mitochondria for prevention or treatment of rheumatoid arthritis |
| US11951135B2 (en) | 2018-07-22 | 2024-04-09 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of muscle diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9912572D0 (en) | 1999-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Polyelectrolyte complex composed of chitosan and sodium alginate for wound dressing application | |
| Singh et al. | Radiation synthesis of PVP/alginate hydrogel containing nanosilver as wound dressing | |
| JP4937269B2 (en) | Sustained release film preparation for wound treatment containing epidermal growth factor | |
| Schaller et al. | Toxicity and antimicrobial activity of a hydrocolloid dressing containing silver particles in an ex vivo model of cutaneous infection | |
| EP2292257A2 (en) | Compositions and methods for dermatological wound healing | |
| CN107617121B (en) | Biological induction active dressing for skin wound surface and preparation method and application thereof | |
| Grzybowski et al. | A new anti‐infective collagen dressing containing antibiotics | |
| JP6290184B2 (en) | Wound dressing | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| Phillips et al. | Cultured allogenic keratinocyte grafts in the management of wound healing: prognostic factors | |
| Han | Interactive wound dressings | |
| GB2350565A (en) | Biological wound dressings comprising mitochondria | |
| US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
| CN113456877B (en) | Organosilicon foam medical dressing and preparation method and application thereof | |
| CN114668885A (en) | Antibacterial healing-promoting functional dressing and preparation method thereof | |
| Uysal et al. | An alternative dressing material for the split-thickness skin graft donor site: oxidized regenerated cellulose | |
| AU2013288698B2 (en) | Novel medical countermeasure for first responder use in burn injury | |
| Lobo Gajiwala et al. | Use of irradiated amnion as a biological dressing in the treatment of radiation induced ulcers | |
| JP2002104974A (en) | Hydrogel therapeutic agent for damaged skin | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| RU2326697C2 (en) | New bandaging material for rapid superficialwound healing | |
| Plettig et al. | Active wound dressing with artificial capillaries for temporary wound irrigation and skin cell supply | |
| RU2545729C1 (en) | Mesh bioactive wound coating | |
| CN102405293A (en) | Membrane of biological fibers, and use thereof | |
| WO2020232456A2 (en) | Improved biosynthetic wound and burn dressing with silver-based broad antimicrobial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) | ||
| 710B | Request of alter time limits |
Free format text: APPLICATION FOR EXTENSION OF THE PERIOD(S) PRESCRIBED BY RULE(S) 33(2) FILED ON 20030214. |